OBR Daily Commentary - ASCO GU Conference Coverage

forumImage

Phase 3 Randomized Trial Data Shows SBRT has Similar Acute Safety Profile to Conventional Radiation Therapy in Patients with Localized Prostate Cancer

(MarketWatch) Feb 22, 2019 - Accuray Incorporated announced today that data from an international, randomized, 38-center trial (PACE - Prostate Advances in Comparative Evidence) show that treatment with stereotactic body radiation therapy (SBRT) results in a similar safety profile to conventional radiation in men with low- or intermediate-risk prostate cancer.

Howard Sandler, MD, MS, FASTRO (Posted: February 22, 2019)

quotesThe PACE (Prostate Advances in Comparative Evidence) trial with two subcomponents: PACE-A and PACE-B is important in prostate cancer radiation and surgical oncology. PACE-B, recently reported some data comparing 'standard, 4-9 week' RT to 'SBRT, 5-fraction' RT, and is showing no difference in acute toxicity. If the tumor control is ultimately shown to be equivalent, then the shorter 5-fraction approach will be widely adopted (adoption is appropriately selective at this point). Results from the highly interesting PACE-A component, comparing surgery to SBRT, (not reported at ASCO GU Cancer Symposium) is eagerly awaited.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men With Metastatic Prostate Cancer

(2019 GU Cancers Symposium) Feb 11, 2019 - A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that progressed despite standard therapies, found that in the majority of men, the cancers were responsive to treatment with a novel, targeted radiation therapy called Lutetium-177 PSMA-617 (LuPSMA). This is the first prospective study of LuPSMA, part of a potential new class of treatments for men with metastatic prostate cancer. According to the researchers, men receiving the medication lived a median of 13.3 months after treatment, longer than the average 9-month survival time for men with this stage of disease. These findings will be presented at the upcoming 2019 Genitourinary Cancers Symposium in San Francisco, California.

Tomasz M. Beer, MD, FACP (Posted: February 13, 2019)

quotesAs contemporary hormonal agents are increasingly used earlier in prostate cancer, the need for novel agents in castration resistant disease is increasingly acute. The promising results with LuPSMA could not come at a better time. We will eagerly await the results of the ongoing phase III trialsquotes

Read Article arrow
Add Comment 1 Comment
forumImage

Bayer to Showcase New Data from its Growing Cancer Portfolio at 2019 ASCO GU Cancers Symposium

(Bayer) Feb 5, 2019 - First presentation of data from the pivotal Phase III ARAMIS trial with the investigational compound darolutamide in patients with non-metastatic castration-resistant prostate cancer.

Tomasz M. Beer, MD, FACP (Posted: February 05, 2019)

quotesDaralutamide would be the third agent with demonstrated efficacy in non-metastatic castration resistant prostate cancer if the ARAMIS trial yields positive results. Both efficacy and safety data will be of interest and clinicians evaluate a growing stable of options in this disease state where enzalutamide and apalutamide have been approved.quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...